Lifotronic(SH:688389)2021-10-22 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥187,979,577.10, representing a year-over-year increase of 40.30%[6] - The net profit attributable to shareholders for Q3 2021 was ¥39,816,776.14, reflecting a significant increase of 70.59% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,652,553.70, up by 57.36% year-over-year[6] - Total operating revenue for the first three quarters of 2021 reached ¥544,056,045.76, a significant increase of 38.5% compared to ¥393,304,492.24 in the same period of 2020[46] - The company's net profit for the third quarter of 2021 was ¥129,142,231.34, compared to ¥105,651,360.04 in the same quarter of 2020, indicating a growth of 22.2%[49] - The net profit attributable to the parent company's shareholders for the first three quarters of 2021 was ¥122,241,966, compared to ¥92,912,031 in the same period of 2020, representing a year-over-year increase of 31.5%[52] - Total comprehensive income attributable to the parent company for the first three quarters of 2021 was ¥122,106,061.14, compared to ¥92,912,031.18 in the same period of 2020, marking a 31.5% increase[54] Research and Development - The total R&D investment for Q3 2021 was ¥46,954,017.62, which accounted for 24.98% of operating revenue, an increase of 1.65 percentage points from the previous year[8] - Research and development expenses increased to ¥118,078,823.31 in 2021 from ¥73,874,742.90 in 2020, marking a rise of 59.7%[49] - The company has developed 2 new products based on its electrochemical luminescence technology platform, focusing on inflammation detection and liver fibrosis detection, with 35 additional chemiluminescence reagent projects completed and submitted for registration review[23] - The company has implemented a product line management and R&D management reform consulting project to improve product development quality and efficiency[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,374,279,448.73, marking a 6.57% increase from the end of the previous year[8] - Total assets as of September 30, 2021, amounted to ¥1,374,279,448.73, an increase from ¥1,289,540,035.62 at the end of 2020[44] - The total liabilities increased to ¥187,562,098.64 in 2021 from ¥145,980,246.67 in 2020, reflecting a growth of 28.5%[44] - The company's equity attributable to shareholders reached ¥1,184,177,032.68, up from ¥1,142,950,841.20, an increase of 3.6%[44] Cash Flow - The company reported a net cash flow from operating activities of ¥81,290,942.95 for the year-to-date, which is a 51.14% increase compared to the same period last year[8] - Cash inflows from operating activities for the first three quarters of 2021 totaled ¥628,563,057.95, compared to ¥449,038,476.30 in the same period of 2020, reflecting a growth of 40%[55] - The net cash flow from operating activities for the third quarter of 2021 was ¥81,290,942.95, an increase of 51.3% compared to ¥53,783,821.31 in the same quarter of 2020[59] - The total cash outflow from investing activities for the third quarter of 2021 was ¥201,675,186.10, compared to ¥609,866,957.08 in the same quarter of 2020, showing a significant reduction of 67.0%[59] - The net cash flow from financing activities for the third quarter of 2021 was -¥80,090,897.38, compared to -¥50,664,000.00 in the same quarter of 2020, indicating a worsening of 57.9%[59] Product Development and Market Strategy - The company obtained 7 product registration certificates during the reporting period, including 5 for rehabilitation and treatment devices and 2 for in vitro diagnostic medical devices, filling product gaps in related treatment and testing areas[27] - The company launched 5 new rehabilitation and treatment products, including shock wave therapy devices and Doppler blood flow detectors, which received medical device registration certificates, providing solid product support for recent performance growth[26] - The company is expected to launch 4 new products in the perioperative and home consumer medical fields in 2023[26] - The company has upgraded key products, including shock wave therapy devices and infrared therapy devices, significantly improving their overall competitiveness[26] - The company initiated a customer relationship management (CRM) project to enhance sales management capabilities, covering both domestic and international markets[33] - The company has started a supply chain relationship management (SRM) project to improve supplier management and order collaboration, enhancing supply chain responsiveness and efficiency[35] Tax and Subsidies - The company received government subsidies amounting to ¥9,250,589.38 during the reporting period, contributing positively to the net profit[9] - The company reported a tax expense of ¥7,036,170.20 for the third quarter of 2021, down from ¥12,739,328.86 in the same quarter of 2020, a decrease of 44.0%[49] - The company received tax refunds amounting to ¥17,961,852.94 in the first three quarters of 2021, compared to ¥14,792,907.02 in the same period of 2020, reflecting a 21.5% increase[55]